Pharmabiz
 

US FDA committee to meet on Multaq on Mar 18, '09

Paris, FranceFriday, December 5, 2008, 08:00 Hrs  [IST]

Sanofi-aventis announced that the US Food and Drug Administration (FDA) has informed the company that they intend to discuss the dronedarone application at the Cardio-Renal Advisory Committee on March 18, 2009. Dronedarone was granted by the FDA a priority review status on July 31, 2008. Dronedarone (Multaq) is an investigational treatment and the only Anti-Arrhythmic Drug (AAD) to have shown a significant reduction in morbidity and mortality in AF/AFL patients with a favourable safety profile as evidenced by a low incidence of pro-arrhythmia (including torsades de pointes) and extra-cardiac organ toxicity.

 
[Close]